Tag: KDC-MN-234

  • Olanzapine

    Atypical antipsychotic

    A thienobenzodiazepine atypical antipsychotic structurally and mechanistically related to clozapine, without the agranulocytosis risk.

    Abstract

    Olanzapine (2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine; CAS 132539-06-1; molecular formula C17H20N4S; molecular weight 312.43) is a thienobenzodiazepine atypical antipsychotic developed at Eli Lilly and approved by the FDA in 1996 under the trade name Zyprexa. The receptor profile is closely related to clozapine: D2 (Ki approximately 11 nM, higher affinity than clozapine), 5-HT2A (Ki approximately 4 nM), H1 (Ki approximately 0.087 nM, among the most potent in clinical use), alpha-1, muscarinic, 5-HT2C, 5-HT3, 5-HT6, 5-HT7. The structural difference from clozapine eliminates the agranulocytosis liability while preserving the broad-spectrum atypical pharmacology. Plasma half-life is 21 to 54 hours; metabolism is via CYP1A2 and direct glucuronidation. The compound carries the highest metabolic risk profile of any commonly used antipsychotic: dyslipidemia, weight gain (mean 4 to 12 kg over 12 weeks), and incident type 2 diabetes are well-documented, attributed to combined H1 and 5-HT2C antagonism. Approved for schizophrenia, bipolar I disorder, and treatment-resistant depression in combination with fluoxetine (Symbyax). Used as a reference broad-spectrum atypical antipsychotic.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.